Company intelligence / Profile preview

SynDermix

Stans, Nidwalden, Switzerlandsyndermix.ch ↗

Ownership: Private
Employees: ~25
Development stage: Phase 2

Overview

SynDermix has demonstrated positive Phase IIa results for its recombinant plant lectin platform in epithelial healing. Its portfolio includes non-invasive medical devices and topical drugs/devices leveraging natural compounds. The company’s assets are at various stages from preclinical to clinical development, with some products approaching commercialization.

Therapeutic areas: PulmonologyDermatologyNeurologyOther
Modalities: DeviceSmall moleculeRecombinant protein
Industry: Biotech

Drug pipeline

1 asset

SDX-21

Preclinical

Partnerships

Strategic partnerships sought for asset development/commercialization; manufacturing partners include biotechnologies manufacturer in Billingham and other service providers in Switzerland and the UK

Beyond the preview

Go deeper on SynDermix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SynDermix.

Explore the full profile